Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
Immuron (NASDAQ: IMRN) has entered into an exclusive distribution agreement to launch ProIBS® in Australia and New Zealand for treating Irritable Bowel Syndrome (IBS) symptoms. The product will join Immuron's portfolio alongside Travelan®.
ProIBS®, developed by Calmino group AB, contains AVH200® derived from Aloe barbadensis Miller and supports the intestinal mucosal barrier. A usability study with 1,003 users showed impressive results: 94% found it helpful, 91% experienced improved daily life, and 98% would recommend it.
The Australian IBS treatment market, part of the 'Digestives & Intestinal Remedies' sector, is projected to generate AU$221.14 million in 2025, with a 3.28% annual growth rate. IBS affects approximately 30% of people, predominantly females, causing symptoms like abdominal pain, bloating, and irregular bowel movements.
Immuron (NASDAQ: IMRN) ha stipulato un accordo di distribuzione esclusivo per lanciare ProIBS® in Australia e Nuova Zelanda per il trattamento dei sintomi della Sindrome dell'Intestino Irritabile (IBS). Il prodotto si unirà al portfolio di Immuron insieme a Travelan®.
ProIBS®, sviluppato da Calmino group AB, contiene AVH200® derivato dall'Aloe barbadensis Miller e supporta la barriera mucosale intestinale. Uno studio di usabilità con 1.003 utenti ha mostrato risultati impressionanti: il 94% lo ha trovato utile, il 91% ha sperimentato un miglioramento nella vita quotidiana e il 98% lo raccomanderebbe.
Il mercato australiano per il trattamento dell'IBS, parte del settore 'Digestivi e Rimedi Intestinali', è previsto generare 221,14 milioni di AUD nel 2025, con un tasso di crescita annuale del 3,28%. L'IBS colpisce circa il 30% delle persone, principalmente donne, causando sintomi come dolore addominale, gonfiore e movimenti intestinali irregolari.
Immuron (NASDAQ: IMRN) ha firmado un acuerdo de distribución exclusivo para lanzar ProIBS® en Australia y Nueva Zelanda para tratar los síntomas del Síndrome del Intestino Irritable (IBS). El producto se unirá al portafolio de Immuron junto a Travelan®.
ProIBS®, desarrollado por Calmino group AB, contiene AVH200® derivado de Aloe barbadensis Miller y apoya la barrera mucosa intestinal. Un estudio de usabilidad con 1,003 usuarios mostró resultados impresionantes: el 94% lo encontró útil, el 91% experimentó una mejora en su vida diaria y el 98% lo recomendaría.
Se proyecta que el mercado australiano de tratamientos para el IBS, parte del sector 'Digestivos y Remedios Intestinales', generará 221.14 millones de AUD en 2025, con una tasa de crecimiento anual del 3.28%. El IBS afecta aproximadamente al 30% de las personas, predominantemente mujeres, causando síntomas como dolor abdominal, distensión y movimientos intestinales irregulares.
Immuron (NASDAQ: IMRN)은 호주와 뉴질랜드에서 과민성 대장 증후군(IBS) 증상을 치료하기 위해 ProIBS®를 출시하기 위한 독점 유통 계약을 체결했습니다. 이 제품은 Immuron의 포트폴리오에 Travelan®과 함께 추가될 것입니다.
Calmino group AB에서 개발한 ProIBS®는 알로에 바르바덴시스 밀러에서 유래한 AVH200®을 포함하고 있으며 장 점막 장벽을 지원합니다. 1,003명의 사용자와 함께 진행된 사용성 연구에서는 인상적인 결과가 나타났습니다: 94%가 유용하다고 느꼈고, 91%가 일상 생활이 개선되었으며, 98%가 추천할 것이라고 응답했습니다.
호주 IBS 치료 시장은 '소화제 및 장 치료제' 부문의 일부로, 2025년까지 2억 2천 114만 호주 달러를 생성할 것으로 예상되며, 연평균 성장률은 3.28%입니다. IBS는 약 30%의 사람들에게 영향을 미치며, 주로 여성에게서 발생하고 복통, 팽만감 및 불규칙한 배변과 같은 증상을 유발합니다.
Immuron (NASDAQ: IMRN) a conclu un accord de distribution exclusif pour lancer ProIBS® en Australie et en Nouvelle-Zélande pour traiter les symptômes du syndrome de l'intestin irritable (IBS). Le produit viendra s'ajouter au portefeuille d'Immuron aux côtés de Travelan®.
ProIBS®, développé par Calmino group AB, contient de l'AVH200® dérivé de l'Aloe barbadensis Miller et soutient la barrière muqueuse intestinale. Une étude d'utilisabilité menée auprès de 1 003 utilisateurs a montré des résultats impressionnants : 94 % l'ont trouvé utile, 91 % ont constaté une amélioration de leur vie quotidienne et 98 % le recommanderaient.
Le marché australien du traitement de l'IBS, qui fait partie du secteur des 'Digestifs et Remèdes Intestinaux', devrait générer 221,14 millions AUD en 2025, avec un taux de croissance annuel de 3,28 %. L'IBS touche environ 30 % des personnes, principalement des femmes, provoquant des symptômes tels que des douleurs abdominales, des ballonnements et des mouvements intestinaux irréguliers.
Immuron (NASDAQ: IMRN) hat eine exklusive Vertriebsvereinbarung unterzeichnet, um ProIBS® in Australien und Neuseeland zur Behandlung von Symptomen des Reizdarmsyndroms (IBS) einzuführen. Das Produkt wird das Portfolio von Immuron zusammen mit Travelan® erweitern.
ProIBS®, entwickelt von Calmino group AB, enthält AVH200® aus Aloe barbadensis Miller und unterstützt die intestinale Schleimhautbarriere. Eine Usability-Studie mit 1.003 Nutzern zeigte beeindruckende Ergebnisse: 94% fanden es hilfreich, 91% berichteten von einer Verbesserung ihres Alltags und 98% würden es weiterempfehlen.
Der australische Markt für IBS-Behandlungen, der Teil des Sektors 'Verdauungs- und Darmentlastungsmittel' ist, wird voraussichtlich bis 2025 221,14 Millionen AUD generieren, mit einer jährlichen Wachstumsrate von 3,28%. IBS betrifft etwa 30% der Menschen, hauptsächlich Frauen, und verursacht Symptome wie Bauchschmerzen, Blähungen und unregelmäßige Stuhlgang.
- Exclusive distribution rights secured for large AU$221.14M market
- Strong product efficacy: 94% positive user response
- Expands product portfolio in growing digestive health sector
- Product already proven successful in Swedish market for over a decade
- Faces competition in crowded digestive health market
- to Australia/New Zealand territories only
Insights
Immuron's exclusive distribution agreement to launch ProIBS® in Australia and New Zealand represents a strategic expansion of its product portfolio in the digestive health market. For a micro-cap company with just
The market opportunity is substantial - with IBS affecting approximately
This agreement leverages Immuron's existing commercial infrastructure and pharmacy channel relationships established through their Travelan® brand, potentially creating operational synergies and cost efficiencies. By adding a complementary product with minimal development costs or regulatory hurdles (as a certified medical device), Immuron is executing a capital-efficient growth strategy appropriate for its size.
However, investors should note the absence of financial terms or exclusivity duration in this announcement. Without disclosure of royalty rates, minimum purchase commitments, or marketing expenditure requirements, it's impossible to quantify the precise revenue impact or timeline to meaningful contribution. The agreement is also geographically to Australia/New Zealand markets only.
Overall, this partnership represents a positive strategic expansion that diversifies Immuron's revenue potential while maintaining focus on their core therapeutic area of digestive health.
MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS® for the treatment of symptoms related to IBS in the retail pharmacy sales channel. Immuron has been a leader in digestive health in Australia for many years. ProIBS® will join Immuron’s product portfolio which includes the rapidly growing Travelan® brand building on the premium efficacy product range that will deliver better outcomes for consumers that Pharmacists will love to recommend.
Irritable bowel syndrome (IBS) is a common condition where you experience symptoms related to your digestive system. This is sometimes linked to certain foods, lifestyle habits and stress levels or mood. IBS affects around 3 out of every 10 people. Females are more likely than males to be affected. Some key symptoms of IBS include: abdominal pain or discomfort; stomach bloating and wind; chronic diarrhoea or constipation, or alternating between the two.1 According to available data, the IBS treatment market in Australia is estimated to be a part of the broader "Digestives & Intestinal Remedies" market, generating a revenue of around AU
ProIBS® is a certified medical device for the treatment of IBS symptoms such as abdominal pain, bloating and unsettled bowel movements (diarrhoea and/or constipation). ProIBS® contains AVH200®, derived from the plant Aloe barbadensis Miller. AVH200® has gel forming components which support the intestinal mucosal barrier. As IBS is known to affect individuals for a long period of time, it is essential to have a treatment appropriate for long-term use – as ProIBS® is. The product is safe, and no interactions with other medications are known. Science-driven innovative Calmino group AB, the developer of ProIBS®, conducted a usability study among 1,003 users. ProIBS® was helpful for
Flavio Palumbo, Chief Commercial Officer said, “Following the rapid growth of Travelan in pharmacy as the leading product for the prevention of traveller’s diarrhoea3, we have identified a great opportunity with ProIBS® to further expand our digestive health portfolio by providing pharmacists a proven premium efficacy product that delivers unique benefits to their customers. With ProIBS®, we are able to provide an innovative and European certified medical device for the treatment of symptoms related to IBS. The product has been on the Swedish pharmacy market for more than a decade. Because it is backed by science and recommended by physicians and dietitians, we can promote ProIBS® with absolute confidence. We are looking forward to offering a solution that truly improves the liveability of the affected people.”
Tobias Kisker, CEO and founder of Calmino group AB, is pleased to start a long and successful collaboration with Immuron. “The Calmino team is happy to work with a well-established, experienced, and professional company like Immuron. We see Australia and New Zealand as important Asian Pacific markets with significant potential.”
- https://www.healthdirect.gov.au/irritable-bowel-syndrome-ibs
- https://www.statista.com/outlook/hmo/otc-pharmaceuticals/digestives-intestinal-remedies/australia
- Otto W, Najnigier B, Stelmasiak T, Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhoea caused by enterotoxigenic Escherichia coli in volunteers. Scandinavian Journal of Gastroenterology. 2011;46:862-868.
This release has been authorised by the directors of Immuron Limited.
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.
For more information visit: https://www.immuron.com.au
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e0632d8c-8807-41a6-ad8f-a65fa3b15f6a
FAQ
What is the market size for IBS treatment in Australia where IMRN will launch ProIBS?
What were the clinical results of ProIBS that IMRN will distribute?
What is the active ingredient in IMRN's new ProIBS treatment?
Which territories are covered in IMRN's new distribution agreement for ProIBS?
